Atezolizumab plus Tiraglolumab — Competitive Intelligence Brief

Atezolizumab plus Tiraglolumab (Atezolizumab plus Tiraglolumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor and TIGIT inhibitor. Area: Oncology.

phase 2 PD-1/PD-L1 inhibitor and TIGIT inhibitor PD-L1 and TIGIT Oncology Small molecule

Target snapshot

Atezolizumab plus Tiraglolumab (Atezolizumab plus Tiraglolumab) — Grupo Espanol Multidisciplinario del Cancer Digestivo. Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atezolizumab plus Tiraglolumab TARGET	Atezolizumab plus Tiraglolumab	Grupo Espanol Multidisciplinario del Cancer Digestivo	phase 2	PD-1/PD-L1 inhibitor and TIGIT inhibitor	PD-L1 and TIGIT

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor and TIGIT inhibitor class)

1. Grupo Espanol Multidisciplinario del Cancer Digestivo · 1 drug in this class